Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Neoplasms 10Carcinoma, Non-Small-Cell Lung 7Ovarian Neoplasms 6Carcinoma, Transitional Cell 6Squamous Cell Carcinoma of Head and Neck 5Neoplasm Metastasis 5Carcinoma, Renal Cell 5Breast Neoplasms 4Triple Negative Breast Neoplasms 3Recurrence 3Melanoma 3Colorectal Neoplasms 3Urinary Bladder Neoplasms 2Sarcoma 2Lymphoma, Follicular 2Lymphoma 2Central Nervous System Neoplasms 2Uveal Melanoma 1Urethral Neoplasms 1Ureteral Neoplasms 1Solid Tumors 1Skin Neoplasms 1Sezary Syndrome 1Prostatic Neoplasms 1Primary Myelofibrosis 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1Mycosis Fungoides 1Metastatic Urothelial Cell Cancer 1Metastatic Solid Tumors 1

Interventions

Vorinostat 2nintedanib 1dactolisib 1avelumab 1Vinorelbine 1Sunitinib 1Hydroxychloroquine 1Dasatinib 1DOXO-EMCH 1Cetuximab 1BN 80927 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Malignant Solid Tumour × avelumab × Clear all
NCT02923466 2022-04-27

Ph1 Administration of VSV-IFNβ-NIS Monotherapy and in Combination With Avelumab in Pts With Refractory Solid Tumors

Vyriad, Inc.

Phase 1 Completed
76 enrolled
Other solid neoplasm

Malignant Solid Tumour

Data powered by HemOnc (CC BY 4.0) Colophon âš¡